FDA’s Cangrelor “Complete Response” Leaves Room For Approval Without New Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency requests additional analyses, but not a new study, supporting the antiplatelet’s use in patients undergoing percutaneous coronary intervention, The Medicines Co. says. However, a second indication in stent thrombosis patients who must stop oral antiplatelet therapy would require a new outcomes trial.